Allergan plc (NYSE:AGN)

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.

Allergan plc (NYSE:AGN)’s Financial Overview

Allergan plc (NYSE:AGN) surged 1.39% yesterday to close its trading session at $192.64. The company has 1 year Price Target of $270.67. Allergan plc has 52-Week high of $322.68 and 52-Week Low of $184.5. The stock touched its 52-Week High on Dec 2, 2015 and 52-Week Low on Nov 23, 2016. The stock traded with the volume of 5.48 Million shares yesterday. The firm shows the market capitalization of $72.26 Billion.

Allergan plc (NYSE:AGN) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $3.32/share against the analyst consensus estimate of $3.56/share. The difference between the actual and expected EPS is $-0.24 a share with a surprise factor of -6.7%.

The firm is trading with SMA20 of -3.01 Percent, SMA50 of -12.14 Percent and SMA200 of -19.81 percent. Allergan plc has P/S value of 4.85 while its P/B value stands at 0.89. Similarly, the company has Return on Assets of 10.3 percent, Return on Equity of 18.7 percent and Return on Investment of -1.3 Percent. The company shows Gross Margin and Operating Margin of 83.3 percent and -9.8 percent respectively.

Many brokerage firms are involved in issuing their ratings on Allergan plc (NYSE:AGN). On 19-Aug-16 Mizuho Upgrade Allergan plc Stock  to Buy. Another firm also rated the stock on 25-Jul-16 where Credit Suisse Initiated the stock to Outperform.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 19 analysts offering 12-month price forecasts for Allergan have a median target of 266.00, with a high estimate of 400.00 and a low estimate of 200.00. The median estimate represents a +38.08% increase from the last price of 192.64.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Banco Santander, S.A. (NYSE:SAN)

Banco Santander SA is the biggest bank in Spain and the biggest international bank in Latin America as well.  The Bank concentrates its activities in Andalucia, Castilla-Leon, Catalonia, Madrid, Valencia and Cantabria.  The Bank provides banking services for individuals and companies, leasing, factoring, stockbrokerage and mutual fund services.

Banco Santander, S.A. (NYSE:SAN)’s Financial Outlook

The 27 analysts offering 12-month price forecasts for Banco Santander have a median target of 5.02, with a high estimate of 5.91 and a low estimate of 3.11. The median estimate represents a +12.10% increase from the last price of 4.48.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Banco Santander, S.A. has a Consensus Recommendation of 3. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 1.59% and closed its last trading session at $4.48. The company has the market capitalization of $66.39 Billion. The stock has 52-week high of $5.43 and 52-Week low of $3.6. The firm touched its 52-Week high on Dec 3, 2015 and 52-Week low on Jun 27, 2016. The company has volume of 5.36 Million shares. The company has a total of 14.82 Billion shares outstanding.

The company has YTD performance of -3.27 percent. Beta for Banco Santander, S.A. stands at 1.64 while its ATR (average true range) is 0.1. The company has Weekly Volatility of 1.25%% and Monthly Volatility of 1.80%%.

Banco Santander, S.A. has distance from 20-day Simple Moving Average (SMA20) of -3.84%, Distance from 50-Day Simple Moving Average of -1.42 percent and Distance from 200-Day Simple Moving Average of 3.11%.

The Company currently has ROA (Return on Assets) of 0.5 percent, Return on Equity (ROE) of 7.1 Percent and Return on Investment (ROI) of 6.5% with Gross margin of 0 percent and Operating & Profit margin of 48.6% and 14.4% respectively.